NCT01339195

Brief Summary

Projections from epidemiological studies suggest that, among the Western adult population, one in three will present a cerebrovascular accident (stroke), severe cognitive disorders, or both. To better diagnose the Vascular Cognitive Impairment, new standards were developed by a North America working group which are under validation. It is essential to adapt these standard for French-speaking population, and especially to define cutoff scores of the cognitive battery to determine cognitive deficit. The investigators propose a study coordinated by the University-Hospital of Amiens for french speaking centers. This study will investigate this battery with 906 controls to define the standards and 302 stroke affected patients to define the frequency and cognitive mechanisms. This step is essential for people to benefit from these new standards.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,635

participants targeted

Target at P75+ for not_applicable stroke

Timeline
Completed

Started Aug 2010

Longer than P75 for not_applicable stroke

Geographic Reach
1 country

7 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2010

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

February 22, 2011

Completed
2 months until next milestone

First Posted

Study publicly available on registry

April 20, 2011

Completed
5.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
Last Updated

September 19, 2025

Status Verified

September 1, 2025

Enrollment Period

6.3 years

First QC Date

February 22, 2011

Last Update Submit

September 16, 2025

Conditions

Keywords

DementiaAlzheimer diseasestrokecognitive impairment

Outcome Measures

Primary Outcomes (1)

  • determine the frequency of cognitive and behavioral disorders 6 months post-stroke assessed with this new NINDS-Canadian Stroke Network battery

    deficit (as compared with control performance) on battery of tests assessing instrumental (oral naming, copy of complex figure)and executive fucntions (verbal fluency, Trail Making, reaction time tests), episodic memory for verbal and visual materials and behavioral changes

    6 month

Secondary Outcomes (2)

  • determine the proportion of patients with dementia

    6 month

  • determine the value of cognitive screening tests

    6 month

Study Arms (1)

Behavioral

EXPERIMENTAL

Behavioral: French adaptation of NINDS-Canadian Stroke Network battery

Behavioral: French adaptation of NINDS-Canadian Stroke Network battery

Interventions

* clinical: post-stroke neurological follow-up assessment * neuropsychological: comprising the NINDS-Canadian Stroke Network neuropsychological battery * MRI

Behavioral

Eligibility Criteria

Age40 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients:management at the acute phase (duration \< 30 days) of stroke visualized by imaging, age between 40 and 80 years, French-speaking, reliable informant, agreeing to participate in the study.
  • Controls: derived from the general population and consenting to participate in the study.

You may not qualify if:

  • Patients: mental retardation, illiteracy, known dementia, schizophrenia or psychosis or history of psychiatric illness requiring a stay for \> 2 days in a psychiatry unit, comorbidities affecting cognition, persistent disturbance of consciousness, contraindication to MRI.
  • Controls: illiteracy, deficit on MMSE (Mini-Mental State Examination), visual, auditory or motor deficit, history of brain disease or psychiatric illness (schizophrenia or other psychosis) or ongoing psychiatric illness (depression or other) currently requiring treatment or requiring a stay \> 2 days in psychiatry unit or anxiety requiring more than one medication at the present time, alcoholism, opiate or illicit drug use \< 3 months, ongoing antidepressant or antiepileptic treatment, recent anxiolytic or hypnotic treatment, general anaesthesia \< 3 months, history of heart surgery with cardiopulmonary bypass

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (7)

CHRU Lille

Lille, Pas-de-calais, 59000, France

Location

CHU Amiens

Amiens, Picardie, 80000, France

Location

CHU Brest

Brest, 29200, France

Location

CHU Dijon

Dijon, 21000, France

Location

CH La Rochelle

La Rochelle, 17000, France

Location

HIA Val de Grâce

Paris, 75000, France

Location

CHU Saint Etienne

Saint-Etienne, 42000, France

Location

Related Publications (6)

  • Godefroy O, Fickl A, Roussel M, Auribault C, Bugnicourt JM, Lamy C, Canaple S, Petitnicolas G. Is the Montreal Cognitive Assessment superior to the Mini-Mental State Examination to detect poststroke cognitive impairment? A study with neuropsychological evaluation. Stroke. 2011 Jun;42(6):1712-6. doi: 10.1161/STROKEAHA.110.606277. Epub 2011 Apr 7.

    PMID: 21474808BACKGROUND
  • Godefroy O, Just A, Ghitu A, Leclercq C, Garcia PY, Lamy C, Canaple S, Bugnicourt JM. The Rankin scale with revised structured interview: effect on reliability, grading of disability and detection of dementia. Int J Stroke. 2012 Feb;7(2):183. doi: 10.1111/j.1747-4949.2011.00743.x. No abstract available.

    PMID: 22264374BACKGROUND
  • Godefroy O; GRECOG-VASC study group; Leclercq C, Bugnicourt JM, Roussel M, Moroni C, Quaglino V, Beaunieux H, Taillia H, Nedelec-Ciceri C, Bonnin C, Thomas-Anterion C, Varvat J, Aboulafia-Brakha T, Assal F. Neuropsychological assessment and cerebral vascular disease: the new standards. Rev Neurol (Paris). 2013 Oct;169(10):779-85. doi: 10.1016/j.neurol.2013.07.009. Epub 2013 Aug 30.

  • Godefroy O, Leclercq C, Roussel M, Moroni C, Quaglino V, Beaunieux H, Tallia H, Nedelec-Ciceri C, Bonnin C, Thomas-Anterion C, Varvat J, Aboulafia-Brakha T, Assal F; GRECOG-VASC Neuropsychological Committee. French adaptation of the vascular cognitive impairment harmonization standards: the GRECOG-VASC study. Int J Stroke. 2012 Jun;7(4):362-3. doi: 10.1111/j.1747-4949.2012.00794.x. No abstract available.

  • Barbay M, Taillia H, Nedelec-Ciceri C, Bompaire F, Bonnin C, Varvat J, Grangette F, Diouf M, Wiener E, Mas JL, Roussel M, Godefroy O; GRECOG-VASC Study Group. Prevalence of Poststroke Neurocognitive Disorders Using National Institute of Neurological Disorders and Stroke-Canadian Stroke Network, VASCOG Criteria (Vascular Behavioral and Cognitive Disorders), and Optimized Criteria of Cognitive Deficit. Stroke. 2018 May;49(5):1141-1147. doi: 10.1161/STROKEAHA.117.018889. Epub 2018 Apr 11.

  • Godefroy O, Yaiche H, Taillia H, Bompaire F, Nedelec-Ciceri C, Bonnin C, Varvat J, Vincent-Grangette F, Diouf M, Mas JL, Canaple S, Lamy C, Arnoux A, Leclercq C, Tasseel-Ponche S, Roussel M, Barbay M; GRECogVASC Study Group. Who should undergo a comprehensive cognitive assessment after a stroke? A cognitive risk score. Neurology. 2018 Nov 20;91(21):e1979-e1987. doi: 10.1212/WNL.0000000000006544. Epub 2018 Oct 17.

MeSH Terms

Conditions

StrokeCognitive DysfunctionMental DisordersDementiaAlzheimer Disease

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesCognition DisordersNeurocognitive DisordersTauopathiesNeurodegenerative Diseases

Study Officials

  • Olivier Godefroy, PhD-MD

    CHU Amiens

    STUDY CHAIR
  • Hilde Henon, MD

    CHRU LILLE

    PRINCIPAL INVESTIGATOR
  • Hervé Taillia, PhD-MD

    HIA val de grace

    PRINCIPAL INVESTIGATOR
  • Serge Timsit, PhD-MD

    CHU Brest

    PRINCIPAL INVESTIGATOR
  • Claudine Nedelec, MD

    CH La Rochelle

    PRINCIPAL INVESTIGATOR
  • catherine thomas, MD

    CHU SAINT-ETIENNE

    PRINCIPAL INVESTIGATOR
  • Maurice Giroud, PhD-MD

    CHU Dijon

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 22, 2011

First Posted

April 20, 2011

Study Start

August 1, 2010

Primary Completion

December 1, 2016

Study Completion

December 1, 2016

Last Updated

September 19, 2025

Record last verified: 2025-09

Locations